Contract analysis

I. Purpose and Scope The purpose of this memorandum is to assess the litigation hazards that Penterra Pharmaceuticals Corp. ("PPC" or the "Company") would face if the Internal Revenue Service's proposed transfer pricing adjustments are not resolved at IRS Appeals and the case proceeds to the United States Tax Court. This analysis has been prepared in connection with the development of PPC's Appeals strategy following

II. Executive Summary of Litigation Hazard Assessment Overall Assessment PPC's transfer pricing positions are well-supported by contemporaneous documentation, robust economic analysis, and a strong factual record of operational substance at Penterra Biopharma Ireland Ltd. ("PBI"). The IRS would face significant hazards in sustaining the full proposed adjustments at trial. Based on our analysis of the individual issue

III. Background A. PPC's IP Structure and Intercompany Arrangements PBI Formation and the Cost-Sharing Arrangement Penterra Biopharma Ireland Ltd. ("PBI") was incorporated on March 15, 2012, under the laws of Ireland, with its registered office and principal place of business in Dublin. Effective July 1, 2012, PPC and PBI entered into a Qualified Cost Sharing Arrangement ("CSA") under Treas. Reg. § 1.482-7. Under the

1. PCT Undervaluation. The IRS valued the PCT at $852 million, compared to PPC's $312 million, and used this purported undervaluation as a basis for recharacterizing the ongoing CSA ratios and royalty rates. The IRS's valuation was prepared by Dr. Washburne using a DCF methodology with a weighted-average cost of capital ("WACC") of 7.2%, compared to PPC's 9.8% WACC.

2. CSA Cost-Sharing Ratio Increase. The IRS proposed increasing PBI's cost-sharing percentage by 8–12 percentage points for each examination year, based on revised RAB calculations incorporating the IRS's higher PCT valuation and different revenue projections.

3. Royalty Rate Increase. The IRS proposed increasing the legacy IP royalty rate from 4.5% to 11.0% of net sales, based on a narrow selection of CUT data from third-party pharmaceutical licensing agreements.

4. Economic Substance Challenge. The IRS asserted that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant, arguing that key DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation) remained in the United States at PPC. Detailed Proposed Adjustments The IRS's proposed adjustments are summarized in the following table: Proposed Penalty. The IRS prop

IV. Hazard Analysis — Issue 1: CSA Cost-Sharing Ratio Adjustments ($235.01M) A. IRS Position The IRS proposes increasing PBI's cost-sharing percentage by 8 to 12 percentage points across each of the four examination years, which would result in additional cost-sharing payments from PBI to PPC totaling $235.01 million. The IRS's proposed percentages and resulting adjustments are as follows: The IRS's position rests on

V. Hazard Analysis — Issue 2: Royalty Rate Adjustment ($188.04M) A. IRS Position The IRS proposes increasing the royalty rate on legacy IP from 4.5% to 11.0% of net sales for PBI's non-Americas territory. This increase would result in additional royalty payments from PBI to PPC totaling $188.04 million across the four examination years, as follows: The IRS's proposed 11.0% royalty rate is based on CUT data from third

VI. Hazard Analysis — Issue 3: Economic Substance Challenge A. IRS Position The IRS asserted that PBI lacked sufficient economic substance to justify its role as IP owner and CSA participant. The IRS's position is grounded in the DEMPE framework—Development, Enhancement, Maintenance, Protection, and Exploitation—and argues that the key DEMPE functions remained in the United States at PPC throughout the examination pe

VII. Hazard Analysis — Issue 4: Correlative Offset ($42.65M) The IRS examination team allowed a correlative offset of $42.65 million in the NOPA to avoid double-counting between the CSA and royalty adjustments. This offset reflects the fact that, to the extent PBI's cost-sharing contributions are increased and its royalties are simultaneously increased, some portion of the additional amounts flowing to PPC would over

VIII. Hazard Analysis — Issue 5: IRC § 6662(e) Penalty ($15.98M) A. IRS Position The IRS proposed the 20% substantial valuation misstatement penalty under IRC § 6662(e) on the full $380.4 million adjustment. The penalty is computed as follows: $380.4M × 21% = $79.88M (estimated underpayment of tax) $79.88M × 20% = $15.98M (rounded) The IRS reserved but did not assert the 40% gross valuation misstatement penalty under